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A PEG hydrogel sealant (PleuraSealTM) is used as an adjunct to standard closure of 
pleural air leaks during lung resection surgery and has demonstrated shorter hospi-
talizations (1.7 days fewer) and more rapid removal of chest tubes in clinical studies 
when compared with standard of care (e.g. staples and sutures alone). Our study was 
designed to estimate the potential cost offsets for using PleuraSealTM compared with 
standard of care in 100 hypothetical patients from a UK hospital who had an air leak 
after lung resection surgery using the cost offset from shorter hospital stays balanced 
against the cost for PleuraSealTM. METHODS: We assumed the cost for PleuraSealTM 
to be £360 per treatment applied to all 100 hypothetical patients compared with no 
added cost for standard of care. We then balanced the added cost for PleuraSealTM 
with the reduction in number of hospital days and subsequent costs compared with 
standard of care (£280/day @1.7 days fewer per patient) and calculated the potential 
cost offsets for PleuraSealTM. RESULTS: A hospital with 100 lung resection surgery 
patients with air leaks can expect to save £11,588, or approximately £17 per patient 
when compared to standard of care as patients who had air leaks stayed in hospital 
an average of 1.7 days longer than those without air leaks. CONCLUSIONS: The cost 
for PleuraSealTM is completely offset by the shorter length of hospital stay compared 
with standard of care. PleuraSealTM is a compelling option for hospitals who perform 
lung resection surgeries as the cost of the treatment is completely offset by the reduc-
tion in air leaks and subsequent hospital stay.
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OBJECTIVES: There is inconclusive evidence on the advantages of branded levalb-
uterol over generic albuterol. This study is the ﬁrst to examine the use and spending of 
these two short-acting beta agonists in a nationally representative sample of Medicare 
patients with COPD enrolled in Medicare Part D. The study also examines patient 
characteristics associated with levalbuterol use and compares the use of other Medicare 
Parts B and D covered COPD medications among albuterol and levalbuterol users. 
METHODS: Data were obtained from the 2005–2006 5% Medicare ﬁles linked to the 
2006 Medicare Part D ﬁles. The sample consisted of all fee-for-service beneﬁciaries with 
COPD enrolled in stand-alone Part D plans in 2006. Patient characteristics and other 
COPD medication use were compared across albuterol-only users, levalbuterol-only 
users, and users of both medications. Multinomial logistic regressions identiﬁed the 
independent factors associated with levalbuterol use. RESULTS: There were 5.5 times 
more albuterol users than levalbuterol users; yet total spending on levalbuterol was 
$169 million whereas on albuterol was $50 million in 2006. Levalbuterol-only users 
were more likely to be older, sicker, and reside in the South than albuterol-only users. 
Part B covered nebulizer formulations were more frequently used among levalbuterol-
only users whereas albuterol-only users were more likely to use inhalers under Part D. 
CONCLUSIONS: Our ﬁndings on the striking differences between levalbuterol and 
albuterol users in terms of spending, patient characteristics, geographic region, and 
drug formulation/device type call for further investigations into these issues as well as 
comparative effectiveness and cost-effectiveness studies of these agents.
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OBJECTIVES: To assess cost-effectiveness of tiotropium (Spiriva®), long-acting anti-
cholinergic agent for Chronic Obstructive Pulmonary Diseases (COPD), and ipratro-
pium in Japan. METHODS: A Markov model was constructed to analyze costs and 
Quality-Adjusted Life Years (QALYs) from the health care payers’perspective. Prior to 
construct the model, we assessed utility scores (disease-speciﬁc SGRQ scores and 
EQ-5D scores) and out-patient medicinal costs among COPD patients visiting Hok-
kaido University Hospital, classiﬁed by COPD severity. Medical costs other than 
medicinal costs (diagnosis, hospitalization, exacerbation, etc) were calculated from 
health insurance claim data in Hokkaido University Hospital. We captured costs and 
outcomes for 5 years. In the Markov model, 1 month was set as one cycle. Both costs 
and utility were discounted at 3% annually. We set the numbers of exacerbations and 
QALYs as outcomes. RESULTS: Both of SGRQ scores and EQ-5D scores were signiﬁ-
cantly inﬂuenced by COPD severity. Average EQ-5D scores for severe/very severe and 
moderate patients were 0.68,and 0.87, respectively. Average SGRQ scores for severe/
very severe and moderate patients were 26.1 and 46.1, respectively. COPD severity also 
signiﬁcantly inﬂuenced out-patient medicinal costs. Per diem out-patient medicinal 
costs of severe/very severe and moderate patients were JPY338 and 135, respectively 
(USD1 = JPY92) . As the results of Markov-model analysis, tiotropium would save 
JPY966,000 or USD10,500 (JPY2,604,000 vs. JPY3,570,000) , reduce the numbers of 
exacerbations (0.46 vs. 0.99) and increase 0.258QALY (3.300 vs. 3.042), compared to 
ipratropium.Various sensitivity analysis, both one-way and probabilistic one, showed 
the robustness of the results. From the budget impact analysis, if whole 220,000 COPD 
patient (based on Patient Survey 2005), use tiotropium instead of ipratropium, we 
would save JPY215 bil or USD2.34bil. CONCLUSIONS: Spiriva® for COPD patients 
in Japan, is thought to be cost-effective and would save health care budget.
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OBJECTIVES: Approximately 4.5 million Canadians, or 18.6% of the total popula-
tion, smoke. Although the prevalence of smoking has shown a signiﬁcantly decreasing 
trend, nicotine dependence remains a major public health issue. A number of phar-
macological treatments are available to help smokers quit such as nicotine replacement 
therapies, bupropion and varenicline. The objective of this study was to evaluate the 
incremental cost-utility ratio of pharmacological anti-smoking treatments. METHODS: 
A Markov model based on the Benesco Simulation model (the Beneﬁts of Smoking 
Cessation on Outcomes) was developed to determine the costs and QALYs associated 
with the nicotine replacement therapies, bupropion and varenicline. This cost-utility 
analysis was performed over a lifetime horizon and from a health care system perspec-
tive. The model considers the health status of smokers, recent non-smokers and long-
term non-smokers; the adverse health outcomes of smoking (asthma, chronic 
obstructive pulmonary disease [COPD], coronary heart disease, stroke and lung 
cancer); and deaths from all causes and from smoking. The model also considers 
smoking cessation probabilities associated with anti-smoking treatments, probabilities 
of resuming, probabilities of complications attributable to smoking, and probabilities 
of death. The costs considered are the costs of anti-smoking treatments according to 
recommended doses and amounts reimbursed by the Régie de l’assurance maladie du 
Québec. RESULTS: Nicotine patches, with higher costs and less QALYs, are domi-
nated by both bupropion and varenicline. Nicotine gum is also dominated by bupro-
pion. Varenicline is the most effective of the anti-smoking treatments studied, albeit 
more costly than nicotine gum and bupropion. The incremental cost-utility ratios for 
varenicline versus nicotine gum and bupropion are respectively $825 and $1,235 per 
QALY. CONCLUSIONS: Results show that varenicline is the most effective option 
of the currently available pharmacological anti-smoking treatments, with a very 
acceptable cost-utility ratio.
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OBJECTIVES: To assess cost effectiveness of Natalizumab, Glatiramer Acetate (GA) 
and Interferon-β in treating patients diagnosed with relapsing-remitting multiple scle-
rosis (RRMS) from a United States (US) patient’s perspective. METHODS: A 30-year 
Markov model was developed with patients transitioning through health states based 
on the Kurtzke Expanded Disability Status Scale (EDSS). Patient health status was 
deﬁned as mild, moderate, or severe when their EDSS score was 0.0–3.5, 4.0–6.0, 
6.5–9.5, respectively. The model was parameterized with data from an extensive lit-
erature review and was adjusted where necessary to 2008 values. Transition probabili-
ties included patients initial distribution based on EDSS score, relapse rate, mortality 
rate, and progression rate. The total cost included direct (inpatient and outpatient 
admissions, ofﬁce visits to physicians, examinations, medication, medical devices, 
alterations to the care, and informal care from family) and indirect costs (productivity 
losses, and early retirement). The utility considered was Quality Adjusted Life-Year 
(QALY). Sensitivity analyses were conducted on all the transition probabilities at a 
range of ± 25% to check the robustness of the result. RESULTS: Based on the result 
of the 30 year Markov Model, patients treated with Natalizumab spend $1,104,773 
to gain 10.47 QALYs, while patients treated with Interferon- β spend $880,199 to 
obtain 9.88 QALYs and for those patients treated with GA have to pay $907,854 to 
yield 7.07 QALYs, which means patients treated with Natalizumab, Interferon-β or 
GA have to spend $105,517, $89,088, $128,409 respectively to gain one QALY. The 
model suggests that Interferon-β is the most cost-effective DMT agent, with an ICER 
of $380,634 per QALY compared with Natalizumab. Compared with GA, the ICER 
for Interferon- β per QALY was $9,841. Sensitivity analysis showed that the results 
were robust to changes in all parameters. CONCLUSIONS: In our study, Interferon-β 
proved to be more cost effective than both Natalizumab and GA for RRMS patients.
PRS29
SMOKING AND WORKPLACE CONSEQUENCES: EVALUATION IN 
FRANCE
Dautzenberg B1, Osman J1, Pibourdin JM2, Charles T3
1OFT, PARIS, France, 2Pierre Fabre, Boulogne cedex, France, 3CREES PFSA, Boulogne, 
France
OBJECTIVES: Tobacco is the primary cause of preventable death in France (66,000 
deaths/Y). Places of work and business are no exception.The objective of this study is 
to gain a better understanding of smoking and its consequences at work, thereby per-
mitting new data to be obtained which will encourage businesses to take smoking into 
account. METHODS: In June 2009, the CSASantéInstitute composed a representative 
sample of the active French population according to the quota method. A total of 1950 
people were interviewed. RESULTS: Of the total active population, there is no signiﬁ-
cant difference according to business size relative to the prevalence of smokers. The 
relationship between smoking and the number of breaks is linear (1 break for 2.5 ciga-
rettes smoked/day). Smokers are subject to even more criticism (because of their break) 
by their colleagues and their hierarchy if they are heavy smokers. Smokers of more than 
1 pack a day tend to be accompanied for their breaks. Smokers have more disrupted 
